Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gastrointestinal 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 12Stomach Neoplasms 10Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Advanced Solid Tumor 9Carcinoma, Hepatocellular 7Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumor 4Melanoma 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Neoplasms 3Lymphoma 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × tislelizumab × Clear all
NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
52 enrolled 23 charts
BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

BeiGene

Phase 1/2 Completed
71 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT06471673 2024-08-26

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

BriaCell Therapeutics Corporation

Phase 1/2 Recruiting
18 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡